Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients

Table 3 Demographic and clinical characteristics of homologous recombination deficiency-positive and -negative ovarian cancer

Characteristic	HRD-positive	HRD-negative
Total, n (%)	6 (24)	19 (76)
Age years at diagnosis, mean ± SD	56.5 ± 11	52.5 ± 13
Positive family history, n (%)	0	5 (26.3)
ECOG PS at diagnosis, n (%)
0	5 (83.3)	17 (89.4)
1	1 (16.7)	1 (5.3)
2	0	1 (5.3)
Histology, n (%)
Serous	5 (83.3)	9 (47.3)
Endometrioid/mucinous/clear cell	1 (16.7)	5 (26.3)
Mixed	0	5 (26.3)
Grade of cancer, mean ± SD	4 ± 0	4 ± 0.9
Stage of cancer, n (%)
1	1 (16.7)	2 (10.5)
2	0	0
3	2 (33.3)	11 (58)
4	3 (50)	6 (31.5)
Surgical Rx, n (%)	6 (100)	17 (89.5)
Primary	2 (33.3)	12 (63.1)
Interval	4 (66.7)	5 (26.4)

Of the 6 homologous recombination deficiency-positive cases, 3 had somatic BRCA gene mutations. ECOG PS: Eastern Cooperative Oncology Group Performance Status; HRD: Homologous recombination deficiency; Rx: Medical prescription.